Vogenx is a clinical-stage life science and drug development company focused on the development of mizagliflozin for the treatment of post-bariatric hypoglycemia (PBH). Mizagliflozin is a small molecule inhibitor of sodium-glucose transporter 1 (SGLT1) with a site of action in the intestinal lumen. Mizagliflozin has been administered to over 500 subjects in 9 clinical studies. The Vogenx team has significant discovery and deve...
Vogenx is a clinical-stage life science and drug development company focused on the development of mizagliflozin for the treatment of post-bariatric hypoglycemia (PBH). Mizagliflozin is a small molecule inhibitor of sodium-glucose transporter 1 (SGLT1) with a site of action in the intestinal lumen. Mizagliflozin has been administered to over 500 subjects in 9 clinical studies. The Vogenx team has significant discovery and development experience in metabolic diseases, including metabolic-related rare diseases.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.